Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01

open access

Page views 302
Article views/downloads 401
Get Citation

Connect on Social Media

Connect on Social Media

No significant risk of hematological malignancy in patients with neurofibromatosis type 1: single center study of children and adults

Agata Marjańska1, Jan Styczyński1, Agnieszka Jatczak-Gaca1, Mariusz Wysocki1
DOI: 10.2478/ahp-2020-0019
Acta Haematol Pol 2020;51(2):102-107.

Abstract

Background/Aim

Neurofibromatosis type 1 (NF1) is characterized by the occurrence of multisystem tumors. The objective of this study was to analyze the demographic and oncological profile of 830 NF1-individuals regarding prevalence, type, and spectrum of malignancy.

Patients and methods

The medical records of patients diagnosed with NF1 with a median age of 22.1 years (range: 0.8–81.6 years) who were followed up for malignancies from 1999 to 2018 were retrospectively reviewed.

Results

The prevalence of malignancy occurring in patients diagnosed with NF1 was 34.8% (289/830). The most common types of neoplasia encompassed tumors strictly associated with NF1, including plexiform neurofibromas (PNF; 200/830; 24.1%) and optic pathway gliomas (91/830; 11%). The prevalence of PNFs-transforming to malignant peripheral nerve sheath tumors (MPNST) was 3.5% (7/200). The prevalence of other tumors was 4.8% (40/830). One patient was diagnosed with acute myeloid leukemia (AML), thus the risk of hematological malignancies among all patients with NF1 was 0.1% (1/830). In the population of patients with malignancies, 43/289 (14.9%) individuals were diagnosed with more than one malignancy.

Conclusions

The odds ratio (OR) of malignancy in a studied cohort of patients with NF1 was 23 ( < 0.001), while the OR of hematological malignancy was 5.1 ( = 0.1) in comparison with the general population.

Article available in PDF format

View PDF Download PDF file